ArticleProbiotics and antimicrobial proteins2026
Bifidobacterium longum subsp. infantis CCFM1445 Promotes Bone Growth in Growing Mice Via Modulating Gut Microbiota and Arginine Metabolism Pathway.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Bifidobacterium has been shown to regulate bone metabolism and maintain bone homeostasis. This study investigated the effects of Bifidobacterium longum subsp. infantis on bone growth in juvenile mice. Treatment with B. longum subsp. infantis CCFM1445 increased femur length, bone volume fraction, and cortical bone area in both female and male mice. Bone histomorphometry indicated that CCFM1445 elevated the height of the femoral growth plate, increased osteoblast numbers, and decreased osteoclast numbers. Furthermore, B. longum subsp. infantis CCFM1445 raised serum concentrations of bone formation markers, including osteoprotegerin (OPG), procollagen type I N-terminal propeptide (PINP), and bone alkaline phosphatase (BALP). Concurrently, it suppressed the levels of tartrate-resistant acid phosphatase type 5b (TRACP5b) and cross-linked N-telopeptide of type I collagen (NTX). Additionally, CCFM1445 upregulated the transcriptional network of key genes involved in osteogenesis and bone matrix synthesis. And intervention with CCFM1445 also significantly increased the relative abundance of Bifidobacterium, Alistipes, and [Eubacterium] xylanophilum group in the gut microbiota. Targeted metabolomic analysis showed that CCFM1445 modulated the arginine biosynthesis and metabolic pathway, characterized by decreased citrulline and increased levels of arginine and its downstream metabolites. Together, these results demonstrate that B. longum subsp. infantis CCFM1445 enhances bone formation, suppresses bone resorption, modulates gut microbiota composition, and influences arginine metabolism, thereby promoting longitudinal bone growth and increasing bone mass in growing mice.
Indexed as
Identifiers
42545608What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.